Eli Lilly and Co LLY

Buzz on the Bullboards: Stocks to watch in volatile times.

[Jonathon Brown]

The TSX hit another record high on strong retail sales data and positive investor sentiment. However, the index quickly fell from grace. read article.

[ApexTrader65]

If Medicare expands to cover GLP-1 drugs, LLY could see a massive demand surge. This is a potential paradigm shift, not just a catalyst. I’m buying dips under $780 in anticipation of this. Also

[ProfitLens2001]

This FDA back-and-forth on Zepbound shortages has me sweating. Short-term noise or a real headwind? I’m holding, but man, they need to clarify fast. Thoughts? Oh, and $MYNZ has been popping up in

[FinancialOrb99]

Just picked up some more $LLY on that dip. Solid fundamentals, and with the obesity drug pipeline, this one feels like a no-brainer for long-term gains. Anyone else averaging down or just me? Also

[whytestocks]

Just In: $LLY Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested doseLilly's muvalaplin lowered lipoprotein(a

[whytestocks]

BREAKING NEWS: $LLY Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now2024-11-17 06:42:00 ET Tesla (NASDAQ: TSLA) is back. Shares of the electric vehicle (EV) maker plunged as

[whytestocks]

News; $LLY A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years2024-10-30 04:45:00 ET For the past couple of years, two of the biggest themes

[PressRelease]

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more...read article.

[whytestocks]

JUST IN: $LLY Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever2024-09-28 05:15:00 ET In the stock market, ups and downs are inevitable. But long-term investors shouldn't get wrapped up

[PressRelease]

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year...read article.

[PressRelease]

Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks...read article.

[PressRelease]

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicalsPatients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeksEBGLYSS delivers long...read article.

[PressRelease]

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facilityNew investment will enhance global medicine production, benefiting millions of patients worldwideINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced...read article.

[PressRelease]

Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial...read article.

[PressRelease]

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD...read article.

[PressRelease]

INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately.Since joining Lilly in 2001...read article.